Last edition
News about "Multiple Sclerosis (MS) treatment"
EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis
The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.
Multiple Sclerosis (MS) Treatment | 25/06/2026 | By News Bureau | 100
Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.
Multiple Sclerosis (MS) Treatment | 09/06/2026 | By News Bureau | 128
Mabwell's 9MW5211 Gains NMPA IND Clearance for Inflammatory Bowel Disease
Mabwell’s 9MW5211 has received IND clearance from China’s NMPA for the treatment of Inflammatory Bowel Disease (IBD). As the first drug candidate globally targeting this novel mechanism to enter clinical development, 9MW5211 represents a significant advancement in the search for innovative therapies for IBD patients.
Multiple Sclerosis (MS) Treatment | 08/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy